Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics (NASDAQ:SRPT) has granted equity awards to 14 new employees hired in November 2024. The awards, approved under the company's 2024 Employment Commencement Incentive Plan, consist of 8,040 restricted stock units (RSUs). These RSUs will vest over four years, with one-fourth vesting annually on the grant date anniversary. The equity awards were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Sarepta Therapeutics (NASDAQ:SRPT) ha concesso premi azionari a 14 nuovi dipendenti assunti nel novembre 2024. I premi, approvati nell'ambito del Piano di Incentivo per l'Inizio dell'Occupazione 2024 dell'azienda, consistono in 8.040 unità di azioni vincolate (RSU). Queste RSU matureranno nell'arco di quattro anni, con un quarto che matura annualmente all'anniversario della data di concessione. I premi azionari sono stati concessi come incentivi all'occupazione in conformità con la Regola 5635(c)(4) del Nasdaq.
Sarepta Therapeutics (NASDAQ:SRPT) ha otorgado premios en acciones a 14 nuevos empleados contratados en noviembre de 2024. Los premios, aprobados bajo el Plan de Incentivo para el Inicio de Empleo 2024 de la compañía, consisten en 8,040 unidades de acciones restringidas (RSUs). Estas RSUs se consolidarán durante cuatro años, con un cuarto consolidándose anualmente en el aniversario de la fecha de concesión. Los premios en acciones se otorgaron como incentivos laborales en cumplimiento con la Regla 5635(c)(4) de Nasdaq.
사레프타 치료제 (NASDAQ:SRPT)는 2024년 11월에 채용된 14명의 신규 직원에게 주식 보상을 부여했습니다. 이 보상은 회사의 2024년 고용 시작 인센티브 계획에 따라 승인되었으며, 총 8,040개의 제한 주식 단위(RSU)로 구성됩니다. 이 RSU는 4년에 걸쳐 분할 지급되어, 부여일의 기념일마다 1/4이 지급됩니다. 주식 보상은 나스닥 상장 규칙 5635(c)(4)에 따라 고용 유인으로 제공되었습니다.
Sarepta Therapeutics (NASDAQ:SRPT) a accordé des récompenses en actions à 14 nouveaux employés recrutés en novembre 2024. Ces récompenses, approuvées dans le cadre du Plan d'Incitation à l'Emploi 2024 de la société, se composent de 8 040 unités d'actions restreintes (RSU). Ces RSU seront acquises sur une période de quatre ans, avec un quart acquérant des droits annuellement à l'anniversaire de la date de l'attribution. Les récompenses en actions ont été accordées comme incitations à l'emploi conformément à la Règle 5635(c)(4) de Nasdaq.
Sarepta Therapeutics (NASDAQ:SRPT) hat 14 neuen Mitarbeitern, die im November 2024 eingestellt wurden, Aktienvergütungen gewährt. Die Vergütungen, die im Rahmen des 2024er Anreizplans für Beschäftigungsbeginn des Unternehmens genehmigt wurden, bestehen aus 8.040 eingeschränkten Aktieneinheiten (RSUs). Diese RSUs werden über vier Jahre ausgegeben, wobei jeweils ein Viertel am Jahrestag des Vergabedatums fällig wird. Die Aktienvergütungen wurden als Anreiz für die Beschäftigung gemäß Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- None.
- None.
The employees received in the aggregate 8,040 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241129198597/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
How many RSUs did Sarepta Therapeutics (SRPT) grant in November 2024?
What is the vesting schedule for Sarepta Therapeutics' (SRPT) November 2024 RSU grants?
Did Sarepta Therapeutics (SRPT) include stock options in their November 2024 inducement grants?
